NA
NKTR icon

NewEdge Advisors’s Nektar Therapeutics NKTR Stock Holding History

NewEdge Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$1.95K – 3979
2024
Q3 		$1.95K Hold
100
– – ﹤0.01% 3385
2024
Q2 		$1.86K Hold
100
– – ﹤0.01% 3353
2024
Q1 		$1.4K Hold
100
– – ﹤0.01% 3441
2023
Q4 		$848 Sell
100
-27
-21% -$204 ﹤0.01% 3483
2023
Q3 		$1.13K Hold
127
– – ﹤0.01% 3155
2023
Q2 		$1.09K Hold
127
– – ﹤0.01% 3230
2023
Q1 		$1.33K Hold
127
– – ﹤0.01% 3113
2022
Q4 		$4 Buy
+127
New +$6.15K ﹤0.01% 3851

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

NewEdge Advisors's NKTR Position: Q4 2024 in Review

NewEdge Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2024, closing a stake of 100 shares — an estimated $1.95K sold.

NewEdge Advisors first reported a position in NKTR in Q4 2022 and held it in 8 quarters. The position peaked at $1.95K in Q3 2024. 143 funds tracked by Wall St. Rank hold NKTR as of Q4 2024.

  • NewEdge Advisors reported no remaining Nektar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • NewEdge Advisors sold 100 Nektar Therapeutics shares in Q4 2024, an estimated $1.95K.
  • NewEdge Advisors first reported a position in Nektar Therapeutics in Q4 2022 and held it in 8 quarters.
  • NewEdge Advisors's Nektar Therapeutics position peaked at $1.95K in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2024.

Based on NewEdge Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.